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Constitutive proteasomes and immunoproteasomes
shape the peptide repertoire presented by major
histocompatibility complex class I (MHC-I) mole-
cules by harboring different sets of catalytically
active subunits. Here, we present the crystal struc-
tures of constitutive proteasomes and immunopro-
teasomes from mouse in the presence and absence
of the epoxyketone inhibitor PR-957 (ONX 0914) at
2.9 A˚ resolution. Based on our X-ray data, we
propose a unique catalytic feature for the immuno-
proteasome subunit b5i/LMP7. Comparison of
ligand-free and ligand-bound proteasomes reveals
conformational changes in the S1 pocket of b5c/X
but not b5i, thereby explaining the selectivity of
PR-957 for b5i. Time-resolved structures of yeast
proteasome:PR-957 complexes indicate that ligand
docking to the active site occurs only via the reactive
head group and the P1 side chain. Together, our
results support structure-guided design of inhibitory
lead structures selective for immunoproteasomes
that are linked to cytokine production and diseases
like cancer and autoimmune disorders.
INTRODUCTION
Nucleated cells of most vertebrates utilize MHC-I molecules to
present peptides to the cell surface. These peptides may be
derived from intracellular self-proteins or have foreign viral or
bacterial origin, but all are products of protein degradation by
the 20S proteasome core particle (CP) (Grant et al., 1995;
Hershko and Ciechanover, 1998; Michalek et al., 1993; Town-
send et al., 1988). When a cytotoxic T cell binds to an immuno-
genic foreign peptide, embedded in the groove of MHC-I
molecules, it is activated to kill the infected antigen-presentingcell (Rock and Goldberg, 1999). The T cell subsequently releases
cytokines, particularly tumor necrosis factor-a and interferon-g,
that induce the expression of three specialized, catalytically
active proteasomal b-subunits, designated b1i/LMP2, b2i/
MECL-1, and b5i/LMP7 (Aki et al., 1994; Brown et al., 1991;
Glynne et al., 1991; Groettrup et al., 1996; Kelly et al., 1991;
Martinez and Monaco, 1991; Nandi et al., 1996). These immuno-
proteasome subunits (i-subunits) cooperatively assemble into
nascent CPs, effectively substituting their constitutive counter-
parts (c-subunits) b1c/Y, b2c/Z, and b5c/X, respectively. Conse-
quently, the de novo synthesis of CPs in inflamed tissues is
largely in the form of immunoproteasomes (iCPs) (Griffin et al.,
1998; Kingsbury et al., 2000). Whereas iCP expression is induc-
ible in most tissues, it is constitutive in hematopoetic cells, espe-
cially lymphocytes and monocytes. Moreover, in cortical thymic
epithelial cells, a third class of mammalian proteasome, the so-
called thymoproteasome (tCP), is expressed, which bears the
subunit b5t and is involved in the positive selection of developing
T cells (Murata et al., 2007).
As a result of their different subunit compositions, constitutive
proteasomes (cCPs), iCPs, and tCPs are endowed with different
cleavage specificities; for example, iCPs preferentially hydrolyze
proteins after nonpolar amino acids (Gaczynska et al., 1994). The
peptides produced by iCPs further stimulate the immune
system, as their hydrophobic C termini are perfect anchor
motifs for binding to MHC-I molecules (Romero et al., 1991).
However, it has been shown in gene-targeted mice that the
i-subunits are not essential for epitope presentation in general,
implying that the cCP is also to a considerable extent competent
in antigen processing (Van den Eynde and Morel, 2001; Yewdell
et al., 1994).
Recent studies reported that b5i plays a pivotal role in cytokine
production, and that small-molecule inhibitors of this subunit
have therapeutic activity in mouse models of autoimmune
diseases and inflammatory disorders (Basler et al., 2010; Ichi-
kawa et al., 2011; Muchamuel et al., 2009). Thus, selective inhi-
bition of the iCP subunit b5i represents a promising therapeutic
alternative to the approved proteasome inhibitor bortezomib,Cell 148, 727–738, February 17, 2012 ª2012 Elsevier Inc. 727
Figure 1. Sequence Alignments of the Catalytic b-Subunits from T. acidophilum and Yeast with Their Murine i- and c-Analogs
Residue numbers are assigned according to the sequence alignment to the b-subunit of T. acidophilum. Amino acid insertions compared to the sequence of
T. acidophilum are designated by additional lowercase letters. Secondary structures (S: b sheet; H: helix) are indicated for the i-subunits. Structurally distorted
amino acids are shown in gray, whereas residues important for the active site are displayed in red. Residues contributing to the substrate-specificity pockets are
highlighted by colored boxes: S1 pocket, green; S2 pocket, blue; S3 pocket, brown; S0, yellow. Amino acid 113 is absent in all b1i-subunits (purple box). The
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which often causes neurotoxicity (Badros et al., 2007). Currently,
the irreversibly acting epoxyketone PR-957 is the most potent
b5i-selective inhibitor (Muchamuel et al., 2009), but the molec-
ular basis for its selectivity has remained elusive up to now.
Here, we examine the murine cCP and iCP at the molecular
level and provide structural explanations for the enhanced
MHC-I antigen generation by iCPs. Moreover, X-ray structures
of the mouse cCP and iCP as well as the CP from Saccharo-
myces cerevisiae (yCP) in the presence and absence of PR-
957 (ONX 0914) revealed the basis for the b5i selectivity of this
compound.
RESULTS
Elucidation of iCP, cCP, and yCP Crystal Structures
in Complex with PR-957
Preparations of iCPs were isolated from livers of BALB/c mice
8 days after infection with lymphocytic choriomeningitis virus
(LCMV), and cCPs were purified from livers of uninfected
b2i/ b5i/ gene-targeted mice (Khan et al., 2001; Schmidtke
et al., 2000). After assessment of their purity by two-dimensional
gel electrophoresis (Figure S1 available online), both proteins
were crystallized from conditions containing 2,4-methyl-penta-
nediol (MPD). Diffraction data of native crystals and crystals
soaked with the epoxyketone inhibitor PR-957 were recorded
to a maximum resolution of 2.9 A˚. Data evaluation with the
coordinates of the bovine cCP (Protein Data Bank [PDB] ID
1IRU; Unno et al., 2002) was followed by positional refinement
as well as model building using 4-fold and 2-fold noncrystallo-
graphic symmetry (NCS) averaging for cCP and iCP, respec-
tively. Electron density maps proved that each subunit was
well defined and that all catalytically active sites of both cCP
and iCP showed full occupancy of PR-957. Positive and
negative Fo-Fc maps clearly depicted expected sequence
changes from c- to i-subunits, allowing us to assign amino
acid side chains unambiguously (Figure 2). Residue numbers
were allocated on the basis of the alignment to the b-subunit
of Thermoplasma acidophilum (Figure 1 and Data S1) (Lo¨we
et al., 1995). All models were completed with final Rfree values
below 27.5% and root-mean-square deviation (rmsd) bond
and angle values of lower than 0.005 A˚ and 0.93 (Table S1).
To explore the docking and the two-step reaction mechanism
of epoxyketones, yCP crystals were soaked with two different
concentrations of PR-957, and X-ray data were evaluated as
previously reported (Groll and Huber, 2005) (Table S2).
Architecture of the iCP
The quaternary structures of the cCP and iCP differ only in the
substitution of the c-subunits b1c, b2c, and b5c by their i-coun-
terparts b1i, b2i, and b5i (Figure 3A). The entry gates to the
central proteolytic chambers are closed by the N termini of thestrictly conserved amino acid exchanges A46S and V127T in b5i, suggested to m
point mutations occupying prominent positions in the substrate-binding channel
(A) The b-subunit of T. acidophilum (tb) is aligned with the b1-subunits from S. c
(B) Alignment of b2-subunits according to (A).
(C) Alignment of b5-subunits according to (A).
See also Data S1.a-subunits, and superposition of the a-rings from cCP and iCP
reveals high structural similarity (rmsd Ca-rings < 0.59 A˚) (Fig-
ure S2). Thus, we speculate that regulation of the gating mecha-
nism by activator complexes such as 19S, 11S (PA28), and
PA200 is similar in cCPs and iCPs.
Structural superposition of identical a-subunits and inactive
b-subunits from both proteasome types shows an rmsd of
<0.35 A˚ for the Ca backbone. Remarkably, the main chain trac-
ings of exchangeable c- and i-b-subunits also match almost
perfectly (rmsd < 0.72 A˚) (Figure 3B), despite the differences in
their primary structures (sequence identity of b1c/b1i: 63.3%;
b2c/b2i: 58.9%; b5c/b5i: 72.4%).
Most amino acid substitutions between murine c- and
i-subunits are surface exposed, and comparison of the primary
sequences of all known c- and i-subunits reveals that only
a few substitutions occur in all species (b1i: 13.6%; b2i: 5.1%;
b5i: 9.8%; Data S1B, S1D, and S1F). Moreover, the number of
interactions that create contact surfaces between neighboring
subunits varies from cCP to iCP (Table S3), but their influence
on the overall stability of the complexes cannot be clarified
from a structural point of view.
Insights into the Substrate-Binding Channels
of the c- and i-Subunits
Substrate affinities toward proteasome active sites are solely
determined by enthalpic interactions with the primed and un-
primed substrate-binding channels (Figure 3C). Whereas
subunits b2i and b2c are identical with respect to their primed
pockets, subunit b1i is shortened by one residue in the region
113–124 compared to b1c (Figure 2A). This deletion is consistent
among all b1i-subunits sequenced thus far and represents a
hallmark feature that changes the possible contact sites for
bound substrates. Similarly, the substitutions S115D and
E116N in subunit b5i may affect cleavage preferences, but these
residues are not conserved among species.
Compared to the primed pockets, the unprimed substrate-
binding channels are far better characterized and can be subdi-
vided in S1, S2, and S3 specificity sites (Figure 3C). Subunit b2i is
the only i-subunit that is not encoded on the MHC cluster; inter-
estingly, its substrate-binding channel was found to be identical
with that of b2c, except for the substitution of Asp53 (b2c) with
Glu (b2i). Furthermore, no differences were observed in the
ligand-free and ligand-bound states (Figures S3A–S3D). Thus,
the rationale for the incorporation of subunit b2i into the iCP
remains elusive, and b2-subunits may play an additional func-
tional role that has yet to be described.
In contrast to the consistent character of subunits b2c and
b2i, several important distinctions were observed upon
comparison of b1c and b1i. The conserved substitutions
T20V, T31F, R45L, and T52A in b1i increase the hydrophobicity
of the S1 pocket and diminish it in size (Figure S3E).odulate the active site characteristics, are indicated by red boxes. Stars mark
or near the active site.
erevisiae (yb1) and M. musculus (mb1c; mb1i).
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Figure 2. Stereo Representation of the Electron
Density of Characteristic Segments of the Murine
c- and i-b-subunits
The electron densities (i-subunits: blue; c-subunits: red)
represent 2Fo-Fc maps, with the displayed amino acids
omitted for phasing. Contouring at even 0.8 s clearly
depicts prominent amino acid exchanges, excluding
a mixture of cCPs and iCPs. Predominantly, exchanges of
bulky residues in the cCP by smaller side chains in the iCP
are shown.
(A) Superposition of the murine subunits b1i (green) and
b1c (gray). The lack of amino acid 113 in the b1i-subunit
results in shortening of the loop segment between Tyr111
and Arg121.
(B) Superposition of the interface of subunits b2i/b1i and
b2c/b1c analogous to (A). The electron density shows
amino acid exchanges, namely Y25A in subunit b1i (green)
and S131Q, L132G, as well as M135V in subunit b2i
(brown).
(C) Superposition of the murine subunits b5i (yellow) and
b5c (gray) visualizes that Tyr88 is replaced by Leu in b5i.
See also Figure S1.Consequently, peptide bond hydrolysis preferentially occurs
after small, hydrophobic, and branched residues and more
epitopes with nonpolar C termini, such as Ile, Leu, or Val, are
generated for the presentation on MHC-I molecules (Cardozo
and Kohanski, 1998; Orlowski et al., 1993; Romero et al.,
1991). This agrees with the specific cleavage of the fluorogenic
model substrate Ac-PAL-AMC (Acetate-Pro-Ala-Leu-7-amino-
methylcoumarin) by b1i (Blackburn et al., 2010). Apart from
the S1 pocket, the amino acid substitutions T22A and A27V
in b1i, as well as Y114H in the adjacent b2i-subunit, collectively
shape, downsize, and polarize the S3 site of the b1i entity
(Figure S3E).
In the S1 pockets of the subunits b5c and b5i, the residues
that give rise to chymotrypsin-like (ChTL) activity, Ala20,
Met45, Ala49, and Cys52, are unchanged. Only amino acid 31
is variable in size but conserved in its hydrophobic character
(Figure S3I and Data S1F). In contrast to b5c-subunits, all known
b5i entities harbor a shallow S2 pocket in position 48 formed by
Cys or Ser. The substitution of Ala27 (b5c) by Ser (b5i) restricts
the size of the S3 pocket of murine and human b5i and endows
it with a more hydrophilic character compared to subunit b5c
(Figure S3I).
In addition to these amino acid changes, the S1 pockets of
b5c and b5i vary in their size. Distinct conformations of
Met45 result in a spacious S1 pocket in b5i and a significantly
smaller one in b5c (Figure S3I). Formation of a large S1 pocket,
similar to chymotrypsin, is favored by strong van der Waals730 Cell 148, 727–738, February 17, 2012 ª2012 Elsevier Inc.interactions of Met45 with the aliphatic side
chain of Gln53. Whereas Gln53 is conserved
in b5i-subunits, it is replaced in b5c-subunits
by Ser, which cannot stabilize Met45 by hydro-
phobic interactions. As a result, b5c harbors
a much smaller S1 pocket and thereby resem-
bles elastase-like activity rather than ChTL
activity. In addition, residue Lys32 (b5c)/Asn32 (b5i) may also be crucial for the distinct architecture of
the S1 pocket in b5c and b5i.
Although the yCP contains Gln53 in yb5, its interaction with
Met45 is less dominant than in b5i; hence, Met45 adopts the
same conformation as observed in b5c. From a structural
perspective, yb5 represents a chimera between b5c and b5i,
as for example Lys32 is conserved in b5c-subunits and Gln53
in b5i entities.
Unique Active Site Architecture of Subunit b5i
The hydrophilicity surrounding the active site nucleophilic
Thr1Og and the oxyanion hole of subunit b5i is increased by
the strictly conserved amino acid exchanges A46S and V127T.
This elevated polarity might favor peptide bond hydrolysis by
attracting water molecules. Moreover, the electron density
displays a unique hydrogen bond network involving Gly47NH,
as well as Ser46Og and Thr127Og (Figures 4C, 4E, and S3I).
Because Ser46Og is directly hydrogen bridged to the oxyanion
hole Gly47NH (3.1 A˚), it may contribute to the stabilization of
the tetrahedral transition state during catalysis. This molecular
feature is unique to b5i and could kinetically favor its proteolytic
activity.
Molecular Basis for the Selectivity of PR-957
for Subunit b5i
In contrast to prominent proteasome inhibitors such as bortezo-
mib, approved for the treatment of multiple myeloma and
Figure 3. Topology of the Murine iCP
(A) Quaternary structure of the iCP drawn as spheres.
(B) Superposition of the Ca chain tracings of b1i (green), b2i (brown), and b5i (yellow) with their constitutive murine (black) and yeast (gray) counterparts,
respectively. N and C termini as well as the nucleophilic Thr1 are labeled.
(C) Illustration of the substrate-specificity pockets of the three proteasomal activities and the S/P nomenclature of ligands. The unprimed (S) pockets, located
N-terminally of the scissile peptide bond (red), and the corresponding substrate residues (P) are colored in blue. The primed (S0) pockets and the respective parts
of the ligand (P0) are highlighted in green. The active site and the nucleophilic water molecule that is incorporated into the cleavage products during hydrolysis are
shown in red.
See also Figure S2.equally targeting the active sites of both b5c and b5i, PR-957
preferentially inhibits subunit b5i of iCPs (Muchamuel et al.,
2009) (Figures 4A, 5, and S4). However, elucidation of the
molecular basis for the selectivity of PR-957 requires the struc-
tural comparison of its binding to all active c- and i-subunits.
Using inhibitor concentrations in the mM range for crystal soak-
ing experiments, PR-957 targeted all active sites of the iCP and
cCP (Muchamuel et al., 2009) as well as yCP and, by covalently
binding in each case, proved that all three distinct catalytic
centers are active in the crystals. Notably, although subunit
b7 was suggested to harbor an active site in the bovine cCP
apo-crystal structure (Unno et al., 2002), it was not occupied
by PR-957 in the cCP and iCP.
The electron density maps display that the C-terminal dipep-
tide of PR-957 forms an antiparallel b sheet in each substrate-
binding channel (Figure 4B), whereas the N-terminal morpholine
moiety is not engaged in any interactions with the protein
(Figures S5A–S5I). In all b2- and b5-subunits, the N-terminal
peptide bond of the inhibitor is further stabilized by a hydrogen
bond involving residue Asp114 of subunits b3 and b6 (Figures
S5A–S5C and S5G–S5I).All b2-subunits harbor very spacious S1 pockets that cannot
sufficiently stabilize PR-957 in the substrate-binding channel
and disfavor ligand binding compared to b5i for energetic
reasons (Figures S3A–S3D and S5A–S5C). In contrast, binding
of PR-957 to b1c is hampered due to steric hindrance by
Arg45, which has to be dislocated to enable covalent modifica-
tion of Thr1. Additionally, the hydrophilic S1 pocket of subunit
b1c opposes binding of the hydrophobic P1 residue of PR-
957. Although the hydrophobicity of the substrate-specificity
pockets of b1i supports PR-957 binding, atomic distances indi-
cate that Phe31 creates a steric barrier to the P1 phenyl moiety of
PR-957 (Figures S3E–S3H and S5D–S5F). Hence, the inhibitor
might bind only against significant repulsive forces mirrored in
an unfavorable orientation of Phe31 toward the carbonyl oxygen
of Asp32 (b1i).
To complement the crystal structures, the IC50 values of
PR-957 for the ChTL activity of various CPs were determined
(Figure 5). Inhibitory activity against murine, human, and yeast
b5c-subunits was observed in the micromolar range (IC50 for
mb5c: 0.92 mM; hb5c: 1.0 mM; yb5: 0.55 mM). In contrast, b5i
from mice and humans displayed IC50 values in the nanomolarCell 148, 727–738, February 17, 2012 ª2012 Elsevier Inc. 731
Figure 4. Structural Basis for the Selective Inhibition of iCPs by
PR-957
(A) Chemical structure of PR-957.
(B) PR-957 molecules bound to b5i, b5c, and yb5 are structurally super-
imposed in the upper panel. The lower panel illustrates the superposition of all
PR-957 molecules bound to yCP, cCP, and iCP, revealing a common binding
mode for the inhibitor backbone. The Thr1 residue is labeled.
(C) Structural superposition of murine subunit b5i alone (gray) and in complex
with PR-957 (yellow) in stereo. Residues Thr1, Gly47, Ser46, and Thr127 are
colored in black; amino acid exchanges apart fromA46S and V127T compared
to subunit b5c are highlighted in magenta. The epoxyketone moiety of PR-957
is marked in cyan and its peptidic backbone in gray. Hydrogen bonds are
indicated by black dashed lines. Reorientation of the CH3-S- group of Met45
upon ligand binding is indicated by a green arrow.
732 Cell 148, 727–738, February 17, 2012 ª2012 Elsevier Inc.range, in agreement with previous studies (mb5i: 65 nM; hb5i:
73 nM) (Muchamuel et al., 2009).
To investigate this phenomenon, b5i-subunits were compared
in the ligand-free and ligand-bound states, showing almost iden-
tical substrate-binding channels. Onlyminor structural reorienta-
tions of the CH3-S- group of Met45, forming the bottom of the
S1-specificity pocket, and Met31 are required to avoid clashing
with the P1 phenylalanine of PR-957 (rmsd Ca b5i/b5i:PR-957:
0.28 A˚) (Figures 4C, 6A, and 6B). However, superposition of
b5c alone and in complex with PR-957 reveals that rotation of
the whole side chain of Met45 is required for binding of PR-
957 (Figures 4D, 6C, and 6D). This structural rearrangement in
the S1-specificity pocket causes the reorientation of Ile35 and
triggers further major conformational changes involving residues
34 to 76. Thus, PR-957 binding to the cCP results in the offset of
the b sheets S4 and S5 as well as a helix H1 by up to 1.7 A˚ (rmsd
Ca b5c/b5c:PR-957: 0.64 A˚). Although superposition of the
ligand-bound subunits b5c and b5i indicates structural similarity
(rmsd Ca b5c:PR-957/b5i:PR-957: 0.55 A˚) (Figures 4E, 6B, and
6D), covalent modification of b5c is hampered by steric
hindrance with Met45, thereby explaining the selectivity of PR-
957 for the ChTL activity of the iCP.
Due to comparable sizes of the S1 pockets of b5c and yb5,
binding of PR-957 to yb5 is also hindered by Met45 and requires
its dislocation (Figures 7D and S6D). Nevertheless, the IC50 value
of PR-957 for subunit yb5 is lower than for b5c (Figure 5), sup-
porting the assumption that yb5 may represent an intermediate
stage between b5c and b5i.Docking of PR-957 to the Active Site Thr1
Epoxyketones such as the natural product epoxomicin and its
structural analog PR-957 have been proposed to react in
a two-step mechanism with the N-terminal Thr1 of catalytically
active proteasome subunits (Groll et al., 2000). To analyze the
docking of the compound to the active site and to prove the
order of reaction steps, we determined the crystal structures of
yCPs incubated for varying times with different concentrations
of PR-957. We obtained two datasets that clearly capture
distinct reaction states of PR-957 with Thr1Og of yb5 (Figures
7A and 7B) and that confirm the formerly proposed mode of
action of epoxyketone inhibitors (Figure 7C). Following a revers-
ible hemiketal formation of Thr1Og with the ketone group of
PR-957 (Figures 7A and 7C), the epoxide is nucleophilically at-
tacked by the amine group of Thr1, leading to the formation of
a morpholine ring by an irreversible intermolecular cyclization
(Figures 7B and 7C).
Remarkably, in the electron density map representing the
hemiketal formation, the intact epoxide of PR-957 and only its
P1 site are structurally defined (Figure 7A). Even though the P1(D) Major structural changes in the substrate pockets of subunit b5c upon
PR-957 binding are shown in stereo and marked by green arrows. Residues
corresponding to the highlighted ones in (C) are color-coded according to (C).
(E) Comparison of the substrate-binding channels of b5i (yellow) and b5c (gray)
after PR-957 binding in stereo representation. Colors are assigned according
to (C) and (D).
See also Figure S3.
Figure 5. Inhibitory Potency of PR-957 for b5-Subunits of Various
CPs
Yeast CP, mouse cCP and iCP, as well as human cCP and iCP were incubated
with varying concentrations of PR-957 (0.001–500 mM). Data from three indi-
vidual experiments were normalized to dimethylsulfoxide (DMSO) treated
controls and are presented as relative activity ± standard deviation. IC50
values are given.
See also Figure S4.site is not yet properly positioned, as indicated by superposition
with the fully reacted PR-957 (Figure 7E), the first docking of
the inhibitor to the active site occurs solely by its reactive
functional group and its interactions with the S1 pocket of the
active b-subunit. Subsequent contacts with the S2 and S3 sites
lead to the formation of an antiparallel b sheet of the peptide
moiety in the substrate-binding channel. Despite the importance
of all three substrate-specificity pockets for the selectivity
of a compound and for its IC50 value, our complex structures
provide evidence that predominantly differences in the S1-
binding pocket, in particular the orientation of Met45, are largely
responsible for the enhanced affinity of PR-957 for b5i compared
to b5c.
DISCUSSION
Our crystallographic data on the cCP and iCP reveal a similar
architecture for c- and i-subunits, which is expected from an
evolutionary point of view. However, our findings highlight the
influence of subtle, yet biologically significant changes that could
not have been predicted based on the existing structures of the
yCP and bovine cCP. The differences in c- and i-subunits
provide an explanation for enhanced antigen processing by
iCPs as well as the molecular basis for the b5i selectivity of the
inhibitor PR-957 and could be elucidated only by comparison
of the six crystal structures reported in this work.
Molecular Differences between the c- and i-Subunits
and Their Implications for Antigen Processing
Due to their high structural similarity, both b2c and b2i are able to
generateMHC-I epitopeswith neutral or basic C-terminal anchor
residues (Rammensee et al., 1995). In addition, as often sug-
gested, the structure of the iCP proves that the b1i substrate-
binding channel is lined with hydrophobic amino acids, which
enhance the production of MHC-I epitopes ending with small,
nonpolar residues (Boes et al., 1994; Groll et al., 1997; Orlowski
et al., 1993). Thus, in b1i-deficient mice, the peptide specificity of
cytotoxic T cell responses is altered (Chen et al., 2001).Apart from b1i, subunit b5i also enhances the generation of
MHC-I ligands (Gaczynska et al., 1994). Our data suggest that
peptide bond hydrolysis might be favored by an increased
hydrophilicity of the active site and additional hydrogen bonds
modulating the oxyanion hole. In particular, the presence of the
strictly conserved residues Ser46 and Thr127 (Data S1F) might
lead to a dominant active site in the iCP, which may explain
the outstanding role of subunit b5i in antigen presentation.
Indeed, increased processing kinetics were reported to stimu-
late the immunogenicity of antigens (Deol et al., 2007), and the
activity of the 26S immunoproteasome was shown to be two
times higher than that of its constitutive counterpart (Seifert
et al., 2010).
In addition, compared to b5c, the introduction of an S2 pocket
in subunit b5i augments its specificity for the P2 site of protein
substrates and might influence its cleavage pattern.
However, most striking is the distinct conformation of Met45
in b5i relative to b5c, leading to differently sized S1 pockets.
The smaller S1 pocket of b5c predominantly accommodates
peptides with tiny hydrophobic amino acids such as Ala or Val.
In contrast, the significantly enlarged S1 pocket of b5i leads to
a preferential cleavage after large nonpolar residues like Tyr
(Gaczynska et al., 1994), Trp, and Phe. These observations agree
with the specific hydrolysis of the known fluorogenic substrates
Ac-WLA-AMC and Ac-ANW-AMC by b5c and b5i, respectively
(Blackburn et al., 2010).
Nonetheless, both ChTL activities display a certain degree of
overlapping substrate specificities, especially with respect to
Leu, Ile, and Tyr. Ligand docking to the active site reveals that
Leu and Ile nicely fit into b5c; however, after initial binding to
the S1 site, Met45 still must perform structural rearrangements
(Figures 7E and S4B). Tyr also induces the dislocation of
Met45, but its hydroxyl group can be stabilized in the S1 pocket
bySer53of subunitb5candSer129of theneighboring subunitb6.
In conclusion, b5i plays a key role in antigen processing by
producing a broad variety of MHC-I epitopes ending with a
branched or spacious hydrophobic anchor residue (Rammensee
et al., 1995). In accord with our hypotheses, b5i- but not b1i- or
b2i-deficient mice show a 50% reduced expression of MHC-I
molecules (Basler et al., 2006; Fehling et al., 1994; Groettrup
et al., 2010; Van Kaer et al., 1994) and are more susceptible to
infectious diseases (Tu et al., 2009). Moreover, as subunit b5i
is involved in cytokine production (Muchamuel et al., 2009), it
may proteolytically activate certain regulatory factors by
cleavage after bulky hydrophobic amino acid residues.
The importance of the ChTL activity for antigen presentation is
further supported by recent studies on the tCP, which differs
from the iCP only by the exchange of subunit b5i with b5t. Lining
of the substrate-binding channel of b5t with the hydrophilic
side chains Ser20, Ser31, Thr45, and Ser49 reduces the ChTL
activity and leads to the production of low-affinity epitopes for
MHC-I receptors (Data S1G). This might be crucial for the posi-
tive selection of developing T cells in the thymus (Murata et al.,
2007; Tomaru et al., 2009; van Endert, 2011).
Based on the structural similarity of CPs, we attempted to
investigate the subtle differences between the subunits b5c
and b5i in more detail. By mutation of key amino acids in yb5,
we tried to mimic main characteristics of subunit b5i in yeast.Cell 148, 727–738, February 17, 2012 ª2012 Elsevier Inc. 733
Figure 6. Conolly Surface Representation of the
b5c and b5i Active Sites in the Presence and
Absence of PR-957
Surface charge distributions are shown for the ChTL
active sites of iCP (A), iCP:PR-957 (B), cCP (C), and
cCP:PR-957 (D). Surface colors indicate positive and
negative electrostatic potentials contoured from 50 kT/e
(intense blue) to50 kT/e (intense red). In order to illustrate
conformational changes, the amino acids 46–50 were
removed. Thr1 is colored in white, and the inhibitor PR-
957, being part of the structures shown in (B) and (D), is
highlighted in yellow. (A) and (C) display the PR-957
molecule of (B) and (D) modeled into the ligand-free
substrate-binding channel by superposition of (A) and (B)
as well as (C) and (D), respectively. Except for the P1
residue, the inhibitor is colored in gray in (A) and (C), as it
does not belong to the displayed structure. Structural
clashes and subsequent rearrangements are marked by
green arrows.
(A) Illustration of the electrostatic potential of the ligand-
free b5i substrate-binding channel. The green arrow
marks the position where the phenyl side chain (yellow) of
PR-957 would touch the CH3-S- group of Met45 of subunit
b5i.
(B) Conolly surface representation of subunit b5i in
complex with PR-957. A steric clash with the phenyl side
chain of the ligand (indicated in A by a green arrow) is
prevented by reorientation of the CH3-S- group of Met45
of subunit b5i (illustrated by the formation of a hole in the
conolly surface and marked by a green arrow). See also
Figure 4C.
(C) Illustration of the ligand-free b5c substrate-binding
channel. Binding of PR-957 to b5c is hampered by severe
clashes of the Phe side chain of PR-957 with Met45 of b5c
(indicated by a green arrow).
(D) Insights into the ligand-bound b5c active site. Reaction of PR-957 with the nucleophilic Thr1 requires major structural rearrangements involving the complete
side chain of Met45 (illustrated by the extension of the hole in the conolly surface and indicated by a green arrow). See also Figure 4D.
See also Figure S5.However, thus far none of themutants displays an affinity for PR-
957 that is comparable to that of mammalian b5i (E.M.H., M.
Groll, W.H., unpublished data). Additionally, exchange of yb5
by the corresponding murine or human i-subunit was lethal to
yeast, even after replacement of their genuine propeptides by
that of yb5. These observations might reflect the different
assembly pathways of the yCP/cCP as well as iCP (Chen and
Hochstrasser, 1996; De et al., 2003; Nandi et al., 1997) and the
high phylogenetic distance between yeast and mouse. Further-
more, our structural data indicate that the amino acids in prox-
imity to the active site and on the contact surfaces to adjacent
subunits form a unique network that is specific for each organism
and, thus, cannot be simply transferred between species.
Structural Requirements for Selective iCP Inhibitors
In autoimmune and neurodegenerative diseases, as well as in
various types of cancer, the levels of proinflammatory cytokines
are elevated resulting in increased iCP expression (Dı´az-Herna´n-
dez et al., 2003; Ho et al., 2007; Puttaparthi and Elliott, 2005;
Singh et al., 2011; Visekruna et al., 2009). In several studies,
the b5i-specific compound PR-957 has been shown to reduce
the level of cytokines and autoantibodies, to modulate cytotoxic
T cell responses, and to prevent disease progression in rheuma-734 Cell 148, 727–738, February 17, 2012 ª2012 Elsevier Inc.toid arthritis, experimental colitis, as well as systemic lupus
erythematosus (Basler et al., 2010; Ichikawa et al., 2011; Mucha-
muel et al., 2009).
Our crystallographic investigations on PR-957 revealed a
binding mechanism common to all active sites of cCP, iCP,
and yCP (Figure 4B), and thus, its selectivity depends, apart
from the reactive warhead, solely on the interactions with the
substrate-binding channel. Furthermore, docking of PR-957
was shown to occur via its functional headgroup and the P1
site. This is consistent with the observation that nonpeptidic pro-
teasome inhibitors such as salinosporamide A and omuralide
target only the S1 pocket (Groll et al., 1997, 2006b). However,
peptidic compounds like PR-957 form an antiparallel b sheet in
the substrate-binding channel, indicating that the P2 and P3
sites also contribute to their specificity.
Based on the following structural requirements, inhibitors
specific for b1c, b1i, b5c, or b5i can now be developed: the S1
pocket of subunit b1c favors negatively charged residues,
whereas the corresponding pocket in b1i accommodates
branched nonpolar side chains. Additionally, comparing
subunits b1c and b1i, the latter prefers smaller and more polar
amino acids in P3. b5c-selective compounds require hydro-
phobic residues like Leu or less structurally demanding amino
Figure 7. Probing the Docking and Reaction Mechanism of Epoxyketone Inhibitors
(A) Stereo representation of yb5 in complex with partially reacted PR-957 still containing the intact epoxide group. Only the electrophilic head group and the P1
site of the partly reacted PR-957 are defined in the electron density. Residues Thr1 and Gly47 are colored in black. The epoxyketone moiety of PR-957 is marked
in cyan, and its peptidic backbone in gray. Hydrogen bonds are indicated by black dashed lines. The 2Fo-Fc electron density for the ligand is shown in blue and is
contoured at 1 s. The inhibitor and Thr1 have been omitted for phasing. Note that PR-957 in this structure was bound only to the ChTL active site of the yCP.
(B) Illustration of subunit yb5 in complex with the fully reacted PR-957 according to (A). In contrast to the partially reacted PR-957 (A), the fully reacted inhibitor
occupies all catalytically active sites (see Figures S5C and S5F, S5J–S5L, and S6).
(C) Schematic representation of the reaction mechanism of epoxyketone inhibitors. Reversible formation of a hemiketal by a nucleophilic attack of Thr1Og on the
ketone group of the inhibitor is followed by an irreversible cyclization involving the N terminus of the proteasomal subunit and resulting in opening of the epoxide
as well as generation of a morpholine ring. Bonds newly formed during this reaction are colored in green. R1 designates the N-terminal part of the inhibitor, R2 the
active b-subunit.
(D) Superposition of the subunits yb5 and b5c, pointing out the structural similarity of both CPs. The side chain Gln53 in yb5, the only sequence difference in the S1
pocket compared to b5c, is marked in magenta. Gly47 and Thr1 are colored in black.
(E) Superposition of PR-957 in its epoxide (ep; yellow) and morpholine (mo; gray) form bound to subunit yb5. Note that during docking, the P1 residue is not yet
properly positioned in the S1 pocket (green arrow). A black dashed arrow marks the position where Thr1NH2 attacks the intact epoxide group, resulting in the
irreversible formation of a secondary amine as part of the morpholine ring.
See also Figure S6.acids in P1 and bulky hydrophobic side chains in P3. In contrast,
inhibitors specific for subunit b5i need large hydrophobic groups
such as Trp or Phe in P1 (Toes et al., 2001) and small polar resi-
dues in P3.
The phenyl side chain of PR-957 perfectly fits into the
spacious S1 pocket of b5i but not into the smaller one ofb5c, which explains the subunit specificity of this inhibitor.
The forces necessary to enlarge the S1 pocket of b5c by
pushing Met45 aside are mirrored in the almost 15 times higher
IC50 value of PR-957 for b5c. Similarly, engineered derivatives
of omuralide and salinosporamide A, with a phenyl moiety in
P1, have been demonstrated to exert significantly reducedCell 148, 727–738, February 17, 2012 ª2012 Elsevier Inc. 735
inhibitory potency toward the ChTL activity of yCP and cCP
compared to the natural products (Corey and Li, 1999; Nett
et al., 2009). Because salinosporamide A (marizomib) is tested
in clinical phase studies (Potts et al., 2011), it would be inter-
esting to characterize the selectivity of these derivatives for
the iCP.
Besides PR-957, our structural data provide an explanation for
the selectivity of well-characterized proteasome inhibitors (Fig-
ure S4A): As carfilzomib, currently in clinical phase 3 trials
(Khan and Stewart, 2011), and PR-825 harbor Leu side chains
in P1 and hydrophobic residues in P3, they both favor subunit
b5c over b5i. Whereas the tripeptidic inhibitor PR-825 is
>10-fold more selective for b5c, the tetrapeptide carfilzomib
displays only slight specificity for b5c (<3-fold), indicating that
P2, P3, and P4 residues also significantly influence the degree
of selectivity (Kuhn et al., 2007; Muchamuel et al., 2009).
In contrast, bortezomib targets both ChTL activities to the
same extent (Demo et al., 2007). Superposition of the murine
CPs with the yCP:bortezomib X-ray structure (Groll et al.,
2006a) reveals that the N-terminal pyrazole ring of bortezomib
can occupy the S3 pocket of both b5c and b5i by interacting
with Thr21, Ala22, and Ala27/Ser27 of b5c/i as well as
Asp114 of b6 (Figure S4B). Based on our crystal structures
and with respect to a sequence identity of more than 90%
between murine and human proteasomal subunits, the selec-
tivity of bortezomib could now be improved for either iCP or
cCP.
In conclusion, the presented crystal structures of cCP and iCP
from the same species enable molecular modeling studies with
both mammalian proteasome classes for the first time. Using
the outline above, it is now possible to undertake the structure-
guided design of inhibitors that target single proteasomal
subunits in order to modulate signaling processes such as
antigen presentation or cytokine production, both of which
play pivotal roles in various diseases. The ability to visualize
the unique characteristics of iCP that evolved to serve immune
responses may offer humankind a therapeutic window of
opportunity.EXPERIMENTAL PROCEDURES
Purification of CPs
Murine cCPs were purified from livers of b2i/ and b5i/ gene targeted mice
as previously described (Schmidtke et al., 2000). To obtain iCP samples,
BALB/c mice were infected intravenously with 200 p.f.u. LCMV-WE leading
to an almost complete conversion to iCPs in the liver on day 8 post-infection
(Khan et al., 2001), when organs were removed. Murine iCPs were purified
from pooled livers (Schmidtke et al., 2000). Human cCPs were isolated from
erythrocytes (Schmidtke et al., 2000), and human iCPs were purchased from
Enzo Life Sciences. yCPs were isolated applying standard protocols (Groll
and Huber, 2005).
Crystallization and Structure Determination of cCP and iCP
cCP and iCP crystals grew from a 1:1 mixture of protein (30 mg/ml) and
reservoir solution (iCP: 0.2 M sodium iodide, 40% MPD; cCP: 0.2 M sodium
formate, 40% MPD). cCP and iCP crystals were soaked with PR-957 at a final
concentration of 3 mM for 8 hr. Structures were solved by molecular replace-
ment using the bovine cCP as a starting model (PDB ID 1IRU) (Unno et al.,
2002) and refined according to standard procedures (see Extended Experi-
mental Procedures).736 Cell 148, 727–738, February 17, 2012 ª2012 Elsevier Inc.ACCESSION NUMBERS
Atomic coordinates have been deposited in the RCSB Protein Data Bank
under the accession codes 3UNH (iCP), 3UNE (cCP), 3UNF (iCP:PR-957),
3UNB (cCP:PR-957), 3UN8 (yCP:PR-957_ep), and 3UN4 (yCP:PR-957_mo).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
six figures, a Data S1 file, and three tables and can be found with this article
online at doi:10.1016/j.cell.2011.12.030.
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